About: Barbara Testoni

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Barbara Testoni Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Testoni, Barbara (19..-....) Testoni, Barbara (19..-....) Testoni, Barbara (19..-....)
alternative label	Destito, Barbara Destito, Barbara Testoni- Testoni-Destito, Barbara
Life Event	http://www.idref.fr/231367791/birth
preferred label	Testoni, Barbara (19..-....)
name	Barbara Testoni
dbpedia-owl:citizenship	http://sws.geonames.org/3175395/
Language	http://lexvo.org/id/iso639-3/ita
Given name	Barbara
familyName	Testoni
has biographical i...tion (Deprecated)	Co-directrice d'une thèse en Virologie soutenue à l'Université de Lyon en 2018 Chargée de recherche à l'université de Lyon depuis 2011. Elle a soutenu une habilitation à diriger des recherches (HDR) sur l'hépatite B à l'université de Lyon en 2023. Elle a une thèse de doctorat PhD en biologie moléculaire et génétique soutenue à l'université de Milan (Italie). Elle a travaillé à l'université Sapienza de Rome (PostDoc). Elle dirige l'équipe de recherche Persistance de l'hépatite B et nouvelle thérapie antivirale. Domaine de recherche : épigénétique, mécanismes de régulation de l'hôte et des gênes viraux pendant l'infection de l'hépatite B, biomarqueurs sériques dans l'activité de l'ADN complémentaire intrahépatique. Elle travaille au CRCL centre de recherche en cancérologie de Lyon. Elle dirige régulièrement des thèses ou est membre de jurys de thèses
gender	female
ORCID iD	0000-0001-5588-5465
Scopus ID	9232908700
is sameAs of	Testoni, Barbara (19..-....) Testoni, Barbara (19..-....) Testoni, Barbara (19..-....)
is Thesis advisor of	http://www.sudoc.fr/254124410/id http://www.sudoc.fr/231368402/id http://www.sudoc.fr/234072776/id http://www.sudoc.fr/262623854/id http://www.sudoc.fr/281403295/id
is Author of	Cas9-targeted nanopore sequencing reveals epigenetic heterogeneity after de novo assembly of native full-length hepatitis B virus genomes Genome-wide identification of direct HBx genomic targets Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis Epigenetic heterogeneity after de novo assembly of native full-length Hepatitis B Virus genomes Gene Editing Technologies to Target HBV cccDNA Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections Viral Diagnosis of Hepatitis B and Delta: What We Know and What Is Still Required? Specific Focus on Low- and Middle-Income Countries HBV 2021: New therapeutic strategies against an old foe Corrigendum to “Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis” [J Hepatol 71 (2019) 763–772] Early inhibition of hepatocyte innate responses by hepatitis B virus Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic hepatitis B Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63 HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes Global strategies are required to cure and eliminate HBV infection Development of hepatocellular carcinoma in chronic hepatitis B patients with advanced fibrosis is independent of viral genotype Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model Clinical relevance of the study of hepatitis B virus covalently closed circular DNA Quantification of the Hepatitis B Virus cccDNA: Evidence-based guidelines for 2 monitoring the key obstacle of HBV cure 3 Short Title: cccDNA quantification harmonization 4 5 HIRA Supports Hepatitis B Virus Minichromosome Establishment and Transcriptional Activity in Infected Hepatocytes Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus Biological basis for functional cure of chronic hepatitis B Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease https://serval.unil.ch/notice/serval:BIB_DD329BAFA656#id https://archive-ouverte.unige.ch/unige:126405#id https://archive-ouverte.unige.ch/unige:101478#id Novel targets for hepatitis B virus therapy Can we cure hepatitis B virus with novel direct‐acting antivirals? Hepatitis B virus targets lipid transport pathways to infect hepatocytes G-quadruplexes control hepatitis B virus replication by promoting cccDNA transcription and phase separation in hepatocytes Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B HBV cure: why, how, when? Hepatitis B Challenges to a Cure for HBV Infection Eliminating cccDNA to cure hepatitis B virus infection Control of Hepatitis B Virus replication by innate response of HepaRG cells Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants Les G-quadruplex favorisent la réplication du virus de l’hépatite B en activant la transcription de l’ADNccc et sa séparation de phase dans les hépatocytes http://hub.abes.fr/edp/periodical/medsci/2022/volume_38/issue_2/msc220009/w
is primary topic of	http://www.idref.fr/231367791
is Opponent of	http://www.sudoc.fr/280241550/id http://www.sudoc.fr/273362828/id
is http//id.loc.gov/vocabulary/relators/aut of	https//hal.archives-ouvertes.fr/hal-04116950id

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software